Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
86,510 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| May 17, 2026 | Capital Blue Cross | Intraocular Lenses, Spectacle Correction,and Iris ProsthesisPayerPolicy · CAPBLUE-MP-6.058 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Interferential Current StimulationPayerPolicy · CAPBLUE-MP-6.047 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Intensive Pediatric Feeding ProgramsPayerPolicy · CAPBLUE-MP-2.079 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Inpatient Interfacility TransfersPayerPolicy · CAPBLUE-MP-3.019 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Injectable Bulking Agents for the Treatment of Urinary and Fecal IncontinencePayerPolicy · CAPBLUE-MP-4.012 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Implantation of Intrastromal Corneal Ring SegmentsPayerPolicy · CAPBLUE-MP-1.044 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Implantable Bone-Conduction and Bone-Anchored Hearing Prosthetic DevicesPayerPolicy · CAPBLUE-MP-1.019 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Hyperthermic Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic MalignanciesPayerPolicy · CAPBLUE-MP-2.021 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Hyperbaric Oxygen Therapy (HBO) (Formerly Hyperbaric Oxygen Pressurization)PayerPolicy · CAPBLUE-MP-2.070 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Hospital Beds and AccessoriesPayerPolicy · CAPBLUE-MP-6.001 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation in the Treatment of Germ-Cell TumorsPayerPolicy · CAPBLUE-MP-9.052 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Waldenstrom MacroglobulinemiaPayerPolicy · CAPBLUE-MP-9.046 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Primary AmyloidosisPayerPolicy · CAPBLUE-MP-9.045 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS SyndromePayerPolicy · CAPBLUE-MP-9.044 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Non-Hodgkin LymphomasPayerPolicy · CAPBLUE-MP-9.042 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in AdultsPayerPolicy · CAPBLUE-MP-9.048 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Hodgkin LymphomaPayerPolicy · CAPBLUE-MP-9.043 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Epithelial Ovarian CancerPayerPolicy · CAPBLUE-MP-9.047 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Chronic Myeloid LeukemiaPayerPolicy · CAPBLUE-MP-9.039 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaPayerPolicy · CAPBLUE-MP-9.038 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for CNS Embryonal Tumors and EpendymomaPayerPolicy · CAPBLUE-MP-9.050 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaPayerPolicy · CAPBLUE-MP-9.040 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Hematopoietic Cell Transplantation for Acute Lymphoblastic LeukemiaPayerPolicy · CAPBLUE-MP-9.041 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Heart/Lung TransplantPayerPolicy · CAPBLUE-MP-9.014 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Heart TransplantPayerPolicy · CAPBLUE-MP-9.007 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | H-Wave Electrical StimulationPayerPolicy · CAPBLUE-MP-6.049 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Germline Genetic Testing for Pancreatic Cancer Susceptibility GenesPayerPolicy · CAPBLUE-MP-2.392 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Germline Genetic Testing for Hereditary Diffuse Gastric Cancer (CDH1,CTNNA1)PayerPolicy · CAPBLUE-MP-2.384 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Germline Genetic Testing for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers (BRCA1, BRCA2, PALB2)PayerPolicy · CAPBLUE-MP-2.211 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Germline Genetic Testing for Gene Variants Associate with Breast Cancer in Individuals at High Breast Cancer Risk (CHEK2, ATM, and BARD1)PayerPolicy · CAPBLUE-MP-2.279 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Germline And Somatic Biomarker Testing (Including Liquid Biopsy) For Targeted Treatment In Prostate Cancer (Brca1/2, Homologous Recombination Repair Gene Alterations, Ntrk Gene Fusion)PayerPolicy · CAPBLUE-MP-2.394 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Germline And Somatic Biomarker Testing (Including Liquid Biopsy) For Targeted Treatment In Ovarian Cancer (Brca1, Brca2, Homologous Recombination Deficiency, Ntrk)PayerPolicy · CAPBLUE-MP-2.395 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Germline And Somatic Biomarker Testing (Including Liquid Biopsy) For Targeted Treatment In Breast Cancer (Brca1, Brca2, Pik3ca, Ki-67, Ret, Braf, Esr1, Ntrk)PayerPolicy · CAPBLUE-MP-2.393 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genotyping for 9p21 Single Nucleotide Polymorphism to Predict Risk of Cardiovascular Disease and AneurysmPayerPolicy · CAPBLUE-MP-2.311 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genotype-Guided Warfarin DosingPayerPolicy · CAPBLUE-MP-2.306 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genotype-Guided Tamoxifen TreatmentPayerPolicy · CAPBLUE-MP-2.307 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing of CADASIL SyndromePayerPolicy · CAPBLUE-MP-2.247 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Predisposition to Inherited Hypertrophic CardiomyopathyPayerPolicy · CAPBLUE-MP-2.248 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Pathogenic FMR1 Variants (Including Fragile X Syndrome)PayerPolicy · CAPBLUE-MP-2.276 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for PTEN Hamartoma Tumor SyndromePayerPolicy · CAPBLUE-MP-2.255 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for NeurofibromatosisPayerPolicy · CAPBLUE-MP-2.358 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Mitochondrial DisordersPayerPolicy · CAPBLUE-MP-2.273 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Marfan Syndrome, Thoracic Aortic Aneurysms and Dissections, and Related DisordersPayerPolicy · CAPBLUE-MP-2.331 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Macular DegenerationPayerPolicy · CAPBLUE-MP-2.260 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Lynch Syndrome and Inherited Colon Cancer SyndromesPayerPolicy · CAPBLUE-MP-5.013 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin TreatmentPayerPolicy · CAPBLUE-MP-2.310 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Limb Girdle Muscular DystrophiesPayerPolicy · CAPBLUE-MP-2.332 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Li-Fraumeni SyndromePayerPolicy · CAPBLUE-MP-2.274 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Inherited ThrombophiliaPayerPolicy · CAPBLUE-MP-2.253 | Criteria changed |
|---|
| May 17, 2026 | Capital Blue Cross | Genetic Testing for Idiopathic Dilated CardiomyopathyPayerPolicy · CAPBLUE-MP-2.328 | Criteria changed |
|---|